Drug addiction: Knockout mice and dirty drugs  by Uhl, George R. et al.
Dispatch 935
Drug addiction: Knockout mice and dirty drugs
George R. Uhl, David J. Vandenbergh and Lucinda L. Miner
Recent studies with knockout mice implicate the
dopamine transporter as the target of the locomotor
effects of the addictive psychomotor drugs cocaine and
amphetamine; studies of reward in these animals are
eagerly awaited.
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The addictive drugs cocaine and amphetamine stimulate
locomotion and provide behavioral reward. They have
multiple molecular sites of action, of which those on
sodium- and chloride-dependent neurotransmitter trans-
porters are thought to be particularly important [1,2].
Both drugs bind to the plasma-membrane transporters for
dopamine, norepinephrine and serotonin, inhibiting reup-
take into neurons of each of these monoamines. Amphet-
amine can also disrupt the hydrogen ion gradient across
the membranes of the synaptic vesicles that store
monoamines, releasing them into the cytoplasm from
where they can be exported out of the cell by mecha-
nisms suggested to include ‘reverse’ transport by the
plasma-membrane transporters [3]. Cocaine also blocks
voltage-gated sodium channels at higher concentrations
[4]. These wide-ranging effects make cocaine and
amphetamine prototypical ‘dirty drugs’, and have led to
persistent uncertainties about which sites contribute to
their locomotor effects and which to their rewarding
behavioral actions. 
The cloning of genes encoding the plasma membrane
monoamine transporters has made it possible to test, by
genetic manipulation, the effects of altering transporter
expression on animal responses to psychostimulant drugs.
The elimination of a response to a drug when one of
several potential sites of action is removed suggests that
that site is necessary for the response. Now Giros et al. [5]
have reported studies using dopamine transporter (DAT)
gene ‘knockout’ mice, which provide evidence that the
dopamine transporter is involved in locomotor responses
to psychomotor stimulant drugs. Homozygous DAT
mutant mice exhibited no locomotor response to ampheta-
mine or cocaine at doses that led to significant responses
in wild-type and heterozygous mice. This result strongly
supports the view that much of the locomotor activation
caused by cocaine and amphetamine can be attributed to
DAT blockade and effects on brain dopamine systems. It
should be noted, however that the mutant mice also
showed behavioural abnormalities in the absence of any
drug — up-to four-fold increases in their nocturnal loco-
motor activity levels — so the observed effects of DAT
gene inactivation on drug responses are superimposed on
differences in baseline levels of locomotion.
The brains of the DAT mutant mice showed expected
alterations in dopaminergic function. Dopamine released
from striatal slices under depolarizing conditions per-
sisted in the extracellular fluid far longer in mutant than
wild-type slices, consistent with a failure of dopamine
reuptake in the mutants. Interestingly,  amphetamine
failed to release dopamine into extracellular fluid perfus-
ing mutant slices, supporting roles for the membrane
transporter in ‘reverse’ transport and/or in amphetamine
accumulation. These important results need to be inter-
preted with caution, however, as the mutant mice show a
number of developmental adaptations to the loss of the
transporter. Thus, their dopamine D1 and D2 receptor
densities are lower than normal. Neurotransmitter pep-
tides in locomotor circuits are altered in the mutant mice,
preproenkephalin expression is substantially downregu-
lated and preprodynorphin expression is somewhat
increased [5]. There may also have been adaptive
changes in systems that were not studied. These adaptive
changes may have contributed to the altered drug-
induced behaviours of the mutant mice, tempering con-
clusions about possible direct roles of the transporter.
There are also pharmacological and genetical considera-
tions in interpreting these data. In a preliminary study on
the C57BL/6J mouse strain that was one of the progeni-
tors of the DAT mutant mice, amphetamine was found to
induce locomotion with a striking, inverted-U-shaped
dose–effect relationship (our unpublished data). The
dose used to test the DAT mutant mice falls on the
descending limb of this curve, so single-dose assessments
cannot distinguish between shifts in drug potency (right-
ward shift in dose-response curves) and reduced drug
responsiveness (downward shift in dose-response curves).
The use of different animal strains with different baseline
activity levels could also complicate matters. The
C57BL/6J and the 129/Sv parental lines of the DAT
mutants differ 3–4-fold in their locomotor activity levels
in a novel environment, while the stress induced by
saline injections elicited much more locomotor activity in
129/Sv than in C57BL/6J mice [6]. These sorts of data
mandate careful attention to the effects of background
genotype, especially in interpreting important but subtle
differences in locomotor responses such as those reported
by Giros et al. [5].
Elevations in spontaneous locomotor activity have been
noted in animals with genetic manipulations affecting
several other genes encoding components of the
dopaminergic system. D1 and D3 receptor knockout mice
showed hyperactivity, or enhanced spontaneous locomo-
tion [7–10]. Conversely, transgenic mice overexpressing
the DAT in catecholaminergic neurons showed unchanged
spontaneous locomotor activities (our unpublished obser-
vations). Different behavioral systems might be engaged to
produce enhanced locomotor stimulation or reduced loco-
motor inhibition through actions in the several distinct cir-
cuits in which neurons express the D1 receptor, D3
receptor or DAT.
The fact that DAT inactivation eliminated the effects of
both amphetamine and cocaine on locomotion could be
viewed as supporting the view that those effects predomi-
nantly reflect drug actions directly on the transporter
itself. But in the case of amphetamine, at least, the effect
could be less direct: loss of the DAT prevents extracellu-
lar release by ‘reverse transport’ of the cytoplasmic
dopamine whose concentrations are enhanced following
amphetamine-induced vesicular release. One way of
testing this idea could come from studies of the tissue con-
tents of dopamine and its metabolites. When we have
examined dopamine content in animals with modest alter-
ations in DAT expression, we have found significant
changes in tissue dopamine levels (our unpublished obser-
vations). Conceivably, amphetamine effects may be
altered as a result of adaptive changes in vesicular
dopamine stores due to loss of the DAT. 
Despite the use of the term ‘indifference’ to cocaine and
amphetamine in the title of their paper, Giros et al. [5] did
not report any direct tests of the motivational effects of
these drugs in the DAT mutant mice. Several studies in
rodents have suggested some parallels between intensities
of drug effects on locomotion and reward systems [11,12],
but recent work has shown that effects on locomotion and
reward are readily separable. Thus, cocaine administration
to D1 receptor knockout mice gave a blunted locomotion
response but a strikingly intact reward response [10].
Several other lines of evidence, however, have suggested
that cocaine reward is largely due to its inhibition of DAT:
lesions of DAT-expressing neurons result in striking
reductions in psychostimulant reward [13,14]; psychostim-
ulants enhance synaptic concentrations of the dopamine
released by DAT-expressing neurons [15]; the relative
potencies of cocaine analogs in tests of behavioral reward
and DAT inhibition correlate well [2]; and transgenic mice
overexpressing DAT in catecholaminergic neurons display
enhanced cocaine-induced reward (our unpublished
observations). The direct examination of cocaine reward
and reinforcement in DAT knockout animals will allow
another test of the idea that DAT is a necessary compo-
nent for cocaine and amphetamine behavioral reward.
The work of Giros et al. [5] serves as a major additional
piece of evidence in support of the view that the DAT has
a central role in the locomotor actions of the ‘dirty drugs’
cocaine and amphetamine. Additional data will be eagerly
sought to test the DAT’s role in the induction of reward
and reinforcement by psychomotor stimulants, and to
assess whether DAT knockout mice really are indifferent
to cocaine and amphetamine. 
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